echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Four clinical Phase III vaccines were given to 60,000 people without serious adverse reactions

    Four clinical Phase III vaccines were given to 60,000 people without serious adverse reactions

    • Last Update: 2020-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Oct. 20 (Xinhua) -- Tian Baoguo, deputy director of the Department of Social Development Science and Technology of the Ministry of Science and Technology, said Tuesday that four new crown vaccines entering phase III clinical trials are progressing smoothly overall, with a total of about 60,000 subjects vaccinated so far and no reports of serious adverse reactions.joint defense control mechanism held a press conference on the 20th to introduce the new crown vaccine related situation. At the meeting, Tian Baoguo introduced the progress of The Vaccine Phase III clinical trial.
    is the most powerful technical tool for controlling infectious diseases, said Mr. Tian. Scientific research team the first time to vaccine research and development as a top priority, layout of inactivated vaccine, recombinant protein vaccine, adenovirus vector vaccine and anti-virus influenza virus vector vaccine and nucleic acid vaccine five technical routes in parallel research and development, the organization of the country's 12 advantages of the team to carry out joint research and development, in strict accordance with the requirements of relevant laws and regulations, in accordance with the procedures, do not lower standards, to ensure safety under the premise of standardized and orderly research and development work.
    said that at present, China's vaccine research and development work is generally in a leading position, each of our technical routes have entered the clinical research stage of the vaccine, specifically, 13 vaccines have entered clinical trials. Among them, inactivated vaccine and adenovirus vector vaccine two technical routes a total of 4 vaccines entered Phase III clinical trials. Four vaccines entering phase III clinical trials are progressing well overall, with a total of about 60,000 subjects vaccinated so far and no reports of serious adverse reactions. Good security was initially shown.
    Tian Baoguo said that the results of Phase III clinical trials are an indicator to verify the internationally recognized effectiveness of vaccine protection, in the current situation of China's new crown epidemic has been effectively controlled, do not have the conditions to carry out Phase III clinical trials, how to select suitable regions and subjects, as well as the smooth organization and implementation of Phase III clinical trials, is currently the main problem facing phase III clinical trials. Next, the scientific research team will follow the scientific law, in accordance with the principle of compliance with the law, and actively promote the research and development of vaccines.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.